Epigenetic Mechanisms in Cancer
161,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in über 4 Wochen
payback
81 °P sammeln
  • Gebundenes Buch

Epigenetic Mechanisms in Cancer provides a comprehensive analysis of epigenetic signatures that govern disease development, progression and metastasis. Epigenetic signatures dictating tumor etiologies present an opportunity for biomarker identification which has broad potential for improving diagnosis, prognosis, prediction, and risk assessment. This volumes offers a unique evaluation of signature differences in childhood, sex-specific and race-specific cancers, and in doing so broadly illuminates the scope of epigenetic biomarkers in clinical environments. Chapters detail the major…mehr

Andere Kunden interessierten sich auch für
Produktbeschreibung
Epigenetic Mechanisms in Cancer provides a comprehensive analysis of epigenetic signatures that govern disease development, progression and metastasis. Epigenetic signatures dictating tumor etiologies present an opportunity for biomarker identification which has broad potential for improving diagnosis, prognosis, prediction, and risk assessment. This volumes offers a unique evaluation of signature differences in childhood, sex-specific and race-specific cancers, and in doing so broadly illuminates the scope of epigenetic biomarkers in clinical environments. Chapters detail the major epigenetic process in humans consisting of DNA methylation, histone modifications and microRNAs (miRNAs) involved in the initiation, progression and metastasis of tumors. Also delineated are recent technologies such as next generation sequencing that are used to identify epigenetic profiles (primarily methylation analysis) in samples (normal, benign and cancerous) and which are highly important to the analysis of epigenetic outcomes.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Autorenporträt
Dr. Saldanha is an Assistant Professor in the Department of Biological Sciences at Alabama State University. Her current research project includes the therapeutic role of histone deacetylase inhibitors in colon and prostate cancers, and her areas of epigenetic interest include epigenetic markers as effective tools in cancer diagnosis. She has more than fifteen years of research experience in cancer epigenetics, protein biochemistry, molecular biology and cloning. She has twelve years of teaching experience and has been a STEM faculty mentor, MARC mentor, and Honor's program project director at ASU. Recently, Dr. Saldanha was named the 2015 National Academies Education Fellow in Life Sciences. She is also currently a Health Disparities Research and Training Program Scholar at UAB and a member of the Cancer Biology Research and Training program at ASU, which was established in 2015. She serves as senior personnel for the ASU-UAB Comprehensive Cancer Center partnership and has been i

nstrumental in developing a cancer biology course at ASU.